🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchBimagrumab + semaglutide — my results so far Page 5

Bimagrumab + semaglutide — my results so far

MaxMetOK Fri, Jan 9, 2026 at 3:38 PM 32 replies 1,200 viewsPage 5 of 7
hans_munich
Member
534
2,345
Jul 2024
Munich, DE
Jan 11, 2026 at 7:58 PM#21
FDA_TrackerJim said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Genuinely useful, thank you. I had the facts and not the framework. Taking it to my next appointment.

18 16kevin_tulsa, Dr.PainCLE, mike_mealprep and 15 others
Reply Quote Save Share Report
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Jan 12, 2026 at 5:03 AM#22

Adding the clinical framing, because it changes how the question reads. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

Last edited: Jan 12, 2026 at 10:03 AM
19 17KristenIndy, MarkLI_maint, Dr.PeteFamMed and 16 others
Reply Quote Save Share Report
fiona_glasgow
Member
312
1,345
Aug 2024
Glasgow, UK
Jan 12, 2026 at 2:08 PM#23
GenomicsKate said:
The mechanism and the magnitude are separate questions.

Second this. The detail I would add is minor and it is already implied above.

20 18KevinCompounds, TirzTom, TrialTracker_MD and 17 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Jan 12, 2026 at 11:13 PM#24
GenomicsKate said:
The mechanism and the magnitude are separate questions.

Adding the part of the answer the thread has not reached. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

Last edited: Jan 13, 2026 at 4:13 AM
21 19tom_AK, josh_phd_bmore, roxy_nash and 18 others
Reply Quote Save Share Report
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Jan 13, 2026 at 8:18 AM#25

Adding the numbers, since they settle part of this. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

22 20Dr.EndoEP, GraceAZ_72, carl_compliance and 19 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register